RECRUITING

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

Talk to us

Conditions

Breast CancerLymphomaHodgkin's LymphomaSexual and Reproductive Healthpremenopausalpostmenopausal12-249Fertility

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the ability to have children (fertility). These blood draws are optional and the patient can still participate in the questionnaire portion of the study even if they choose not to have their blood drawn.

Official Title

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma

Quick Facts

Study Start:2013-02
Study Completion:2025-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01788839

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Women, 18 years of age and older
  2. * Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months
  3. * Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.
  4. * Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.
  5. * Breast cancer patients with any receptor type
  6. * English speaking
  7. * Able to participate in the informed consent process
  8. * Women, 18 years of age and older.
  9. * Premenopausal women at time of diagnosis who have either been pregnant or had at least one menstrual period in the last 12 months
  10. * Note: premenopausal women at time of diagnosis who have not been pregnant or have not had at least one menstrual period in the last 12 months are able to participate only if they have had an intrauterine device (IUD) in place within the last 12 months.
  11. * Women with newly diagnosed breast cancer (stage 0-III) who have not yet started treatment and are planning to start Tamoxifen as their only form of systemic treatment within one month
  12. * Breast cancer patients with any receptor type
  13. * English speaking
  14. * Able to participate in the informed consent process
  15. * Women, 18 years of age and older.
  16. * Postmenopausal women at time of diagnosis who have been without period for ≥ 2 years.
  17. * Women with newly diagnosed breast cancer (stage 0-III) who are within 1 month of starting systemic treatment or women with any aggressive lymphoma being treated with first line therapy with curative intent.
  18. * Breast cancer patients with any receptor type
  19. * English speaking
  20. * Able to participate in the informed consent process
  1. * Active secondary cancer requiring cytotoxic chemotherapy
  2. * Prior systemic treatment for a malignancy

Contacts and Locations

Study Contact

Shari Goldfarb, MD
CONTACT
646-888-5080
Jeanne Carter, MD
CONTACT
646-888-5076

Principal Investigator

Shari Goldfarb, MD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920
United States
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748
United States
Memorial Sloan Kettering Bergen
Montvale, New Jersey, 07645
United States
Memorial Sloan Kettering Commack
Commack, New York, 11725
United States
Memorial Sloan Kettering Westchester
Harrison, New York, 10604
United States
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Shari Goldfarb, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2013-02
Study Completion Date2025-02

Study Record Updates

Study Start Date2013-02
Study Completion Date2025-02

Terms related to this study

Keywords Provided by Researchers

  • Sexual and Reproductive Health
  • premenopausal
  • postmenopausal
  • 12-249
  • Fertility

Additional Relevant MeSH Terms

  • Breast Cancer
  • Lymphoma
  • Hodgkin's Lymphoma